PropertyValue
?:abstract
  • There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-BarrĂ© syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.
?:creator
?:doi
?:doi
  • 10.1007/s13365-020-00884-7
?:journal
  • J_Neurovirol
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/d0a66453a29c0151a7569e4ded8bd9703cbc75b9.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7384559.xml.json
?:pmcid
?:pmid
?:pmid
  • 32720233.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Severe rapidly progressive Guillain-BarrĂ© syndrome in the setting of acute COVID-19 disease
?:type
?:year
  • 2020-07-27

Metadata

Anon_0  
expand all